Dotriacontanol

Dotriacontanol: A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Nomenclature

1-Dotriacontanol is a fatty alcohol with 32 carbon atoms. Its IUPAC chemical name is dotriacontan-1-ol, with synonyms including Laccerol, NSC 53834, n-dotriacontanol, and the CAS registry number 6624-79-9. Its molecular formula is C₃₂H₆₆O and molecular weight is 466.87 g/mol. The compound is sometimes listed in databases under the entry 1-Dotriacontanol, reflecting the IUPAC convention of placing the hydroxyl group at the terminal (C-1) carbon. Additional synonyms recorded in chemical databases include dotriacontyl alcohol, 1-hydroxytriacontane, and myricyl alcohol (the last name is also shared with closely related alcohols).

Structure and Physical Properties

1-Dotriacontanol is a long-chain fatty alcohol with the chemical formula C₃₂H₆₆O, characterized by a straight-chain structure consisting of 32 carbon atoms and a hydroxyl (–OH) functional group at one end. According to ChEBI, it is formally a long-chain primary fatty alcohol that is dotriacontane in which a hydrogen attached to one of the terminal carbons is replaced by a hydroxy group. The compound is typically a white, waxy solid at room temperature and is insoluble in water but soluble in organic solvents such as ethanol and chloroform. It belongs to the broader class of very long-chain fatty alcohols (VLCFAs), which encompasses saturated primary alcohols with 20 or more carbon atoms.

Position in the Policosanol Family

Dotriacontanol (C-32) is a member of the policosanol group — the collective term for mixtures of long-chain aliphatic primary alcohols derived from plant and animal waxes. Policosanols are high-molecular-weight, long-chain aliphatic primary alcohols, known as tetratriacontanol (C-34), dotriacontanol (C-32), triacontanol (C-30), nonacosanol (C-29), octacosanol (C-28), heptacosanol (C-27), hexacosanol (C-26), and tetracosanol (C-24). Within any given wax source, dotriacontanol is typically a minor-to-moderate constituent rather than the dominant alcohol.

2. Natural Sources

Plant Waxes

Dotriacontanol is a natural plant-derived compound found primarily in epicuticular waxes on the surfaces of leaves and other plant parts. It has been specifically documented in Prosopis glandulosa and Euphorbia granulata. Phytochemical studies have identified it in a wider range of botanicals:

• Tridax procumbens (Asteraceae): Nine known compounds isolated for the first time from the plant were identified as dotriacontanol, β-amyrone, Δ¹²-dehydrolupen-3-one, β-amyrin, lupeol, fucosterol, 9-oxoheptadecane, 10-oxononadecane and sitosterol.
• Malvastrum coromandelianum (Malvaceae): Phytoconstituents reported from aerial parts of the plant include β-phenylethylamine, dotriacontane, dotriacontanol, β-sitosterol, stigmasterol, campesterol, lutein, N-methyl-β-phenylethylamine, and indole alkaloids.
• Cassia alata (Fabaceae): The plant is a source of chrysoeriol, kaempferol, quercetin, and related flavonoids alongside n-dotriacontanol and n-triacontanol.
• Agrimonia pilosa (Rosaceae): Nineteen compounds were isolated and identified from Agrimoniae Herba, including β-sitosterol, dotriacontanol, hentriacontanol, nonadecanoic acid, and other compounds.
• Bougainvillea × buttiana (Nyctaginaceae): A previous phytochemical study identified BxbRAE-100% as composed of the carbohydrate O-3-methyl-d-glucose (16.80%), the saturated fatty acid n-hexadecanoic acid (23.10%), the polyunsaturated acid (9-Z,12-Z)-9,12-octadecanoic acid (19.90%), and the fatty alcohol 1-dotriacontanol (19.90%).
• Red Yeast Rice (Monascus purpureus-fermented rice): Among nine other compounds isolated from red yeast rice (RYR), 1-dotriacontanol was characterized and reported.

Sugar Cane Wax (Saccharum officinarum)

Sugar cane is the most commercially studied source of policosanol. Policosanol (PCO) is a mixture of aliphatic alcohols ranging from 24 to 34 carbon atoms refined from sugar cane wax (Saccharum officinarum L.), namely octacosanol, triacontanol, and dotriacontanol, hexacosanol, and tetratriacontanol as major components. PCO contains four major components, namely octacosanol (60–70%), triacontanol (10–15%), dotriacontanol (5.0–10%), and hexacosanol (3.0–10%). Other alcohols such as tetracosanol, nonacosanol, tetratriacontanol, and heptacosanol are minor components.

Rice Bran Wax

Rice bran wax is composed of policosanol, which includes bioactive compounds with clinical properties for human health. The major form of policosanol in commercial rice bran cooking oils was tetracosanol (C24), followed by dotriacontanol (C32), while the main form in functional rice bran oil was dotriacontanol (C32), followed by octacosanol (C28), and tetracosanol (C24). The bran of Thai rice varieties contains triacontanol, dotriacontanol, and tetratriacontanol as their main components.

Corn (Maize) Kernel

Corn pericarp policosanol was mainly triacontanol (33.63–46.29 mg/kg), dotriacontanol (22.31–39.46 mg/kg), and octacosanol (8.13–14.0 mg/kg). In contrast, the corn germ fraction contained mostly dotriacontanol (more than 50%) and no triacontanol. This makes the corn germ fraction uniquely dotriacontanol-dominant among common policosanol sources.

Beeswax

Beeswax also contains a significant quantity of long chain primary alcohols in both the free and esterified forms. Polycosanol compositions isolated from beeswax contain 24 to 34 carbon atoms (C24–C34) comprised of tetracosanol (9–15%), hexacosanol (12–18%), octacosanol (13–20%), triacontanol (20–30%) and dotriacontanol (13–21%). Notably, dotriacontanol represents a substantially higher proportion of beeswax policosanol than it does in sugar cane wax.

Chinese White Wax Scale Insect (Ericerus pela)

Ericerus pela, which belongs to the family Coccidae, is an insect indigenous to southern China, having the common name white wax scale. The polycosanol profile of this material included octacosanol as the major component (60–70% content), followed by triacontanol (10–15%), hexacosanol (5.5–8.5%), dotriacontanol (4–6%), heptacosanol (2–3.5%), tetratriacontanol (0.4–2.0%), nonacontanol (0.4–1.2%) and tetracosanol (0.5–1.0%).

Wheat and Other Cereals

Although PCO is widely distributed in beeswax, rice bran, wheat germ, grapes, apples, etc., it was first obtained by Cuban researchers from sugarcane wax (Saccharum officinarum L.). Dotriacontanol is present among policosanol constituents in various cereal brans and germs, though at lower concentrations than in rice bran.

3. Traditional and Historical Use

Chinese Folk Medicine — Ericerus pela (White Wax)

The use of wax from the white wax scale insect (Ericerus pela) in traditional Chinese medicine predates modern pharmacological investigation. The wax has traditionally been used for bleeding, pain relief, wound healing, coughing, and diarrhea. Dotriacontanol is among the long-chain fatty alcohols contained in this wax, though traditional preparations would not have isolated individual constituents.

Red Yeast Rice in East Asian Medicine

Red yeast rice (RYR) is a traditional Chinese medicine and food supplement popular in East Asian countries such as China, Japan, Korea, and Thailand. It is produced by the fermentation of cooked rice kernels with a Monascaceae mold, Monascus purpureus, which turns rice into reddish purple kernels due to its pigmentation capability. The production of red yeast rice was used as a Chinese folk medicine, recorded in old Chinese literature as a means of easing digestion and soothing pain. Dotriacontanol has been documented as an isolate from RYR, though it is one of many constituents and was not historically recognized as an individual pharmacological agent.

Ayurvedic and South Asian Traditions — Tridax procumbens

Tridax procumbens is a major medicinal plant used since before recorded history in both organized (Ayurveda, Unani) and unorganized (folk, tribal, indigenous) traditional medicine practices. In Ayurveda, T. procumbens is used as a herbal drug for wound cure. The practice common amongst farmers of Indian villages is to crush the fresh leaves and let the juice cover the dermal wound. Dotriacontanol is among the lipid constituents isolated from this plant, though the traditional applications applied the whole-plant extract rather than isolated compounds.

Beeswax in Antiquity

Beeswax has been used since antiquity in a great variety of cosmetic and therapeutic applications, as a base for lipstick, in lotions and creams, as an emollient, and as a constituent in therapeutic products for topical and membrane application. Dotriacontanol is present in beeswax as part of its long-chain alcohol complement, and its contribution to any specific traditional use cannot be separated from that of the broader mixture.

Cuban Sugar Cane Policosanol (from the 1990s)

The modern supplement history of dotriacontanol as a component of policosanol mixtures is associated with Cuban research initiated in the early 1990s. Early clinical studies showed that oral administration of sugar cane policosanol within a range of 5–20 mg/day reduces plasma total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels and increases high-density lipoprotein cholesterol (HDL-C) in healthy and hypercholesterolaemic individuals. Sugar cane policosanol (SCP) was used in Cuba as a dietary supplement since the early 1990s. Today, Cuban SCP and policosanol isolated from other sources are widely used in supplements for hypercholesterolemia.

4. Key Constituents, Co-Occurring Compounds, and Context Within Policosanol Mixtures

Dotriacontanol is virtually never encountered as a single isolated ingredient in commercial supplements; rather, it is present as a constituent within whole policosanol preparations. Understanding its activity therefore requires context within those mixtures.

Proportional Presence in Major Policosanol Sources

The most prevalent alcohol in policosanol is octacosanol, followed by triacontanol. There is a much lower concentration of several other fatty alcohols: behenyl alcohol, lignoceryl alcohol, ceryl alcohol, 1-heptacosanol, 1-nonacosanol, 1-dotriacontanol, and geddyl alcohol. In sugar cane–derived policosanol, dotriacontanol constitutes approximately 4–10% of the total mixture. In beeswax-derived preparations, its relative share rises substantially to 13–21%.

Presence in Red Yeast Rice

Among nine other compounds isolated from RYR, 1-dotriacontanol (compound 92) was identified and characterized. It is one component of the complex phytochemical profile of RYR, which also includes monacolins (including monacolin K / lovastatin), azaphilones, sterols, and other fatty acids and alcohols.

5. Mechanisms of Action

The following mechanisms apply to policosanol mixtures of which dotriacontanol is a constituent. Because no human clinical trials have studied dotriacontanol in isolation, its individual contribution to these mechanisms is not established. The discussion covers the pharmacology of the policosanol class as a whole.

HMG-CoA Reductase Modulation

Policosanol's impact on cholesterol is mediated through a reduction in the synthesis and degradation of the rate-limiting step of cholesterol biosynthesis, the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. Cuban authors showed that SCP inhibits hepatic cholesterol synthesis prior to the formation of mevalonate, reducing synthesis and increasing degradation of HMG-CoA. Other studies demonstrated that SCP reduces HMG-CoA activity via AMP-kinase phosphorylation. The underlying mechanism of action by which policosanol lowers cholesterol has not been definitively elucidated but is proposed to include inhibition of cholesterol synthesis by down-regulating the cellular expression of hydroxymethylglutamyl coenzyme A reductase.

LDL Receptor Upregulation and Enhanced Catabolism

Policosanol increases significantly, and in a dose-dependent manner, the binding and hepatic uptake of LDLs, with a consequent positive acceleration of their catabolism. The exact mechanism of action of policosanol for lipid lowering has not been sufficiently elucidated, but has been associated with suppression of cholesterol synthesis as well as stimulation of the degradation of LDL cholesterol in liver cells by activating lipases.

Inhibition of LDL Peroxidation

Various studies in vitro and in vivo have demonstrated that policosanol exerts an antioxidant action with consequent inhibition of the peroxidation of LDLs and VLDLs. Blocking of the peroxidation of LDLs, also confirmed by human clinical trials, leads to an important antiatherogenic effect, because LDLs only exert their atherogenic action in the oxidized state.

Antiplatelet Effects

Policosanol decreases levels of thromboxane A2 and may increase levels of prostacyclin. In addition, large doses can inhibit platelet aggregation induced by arachidonic acid and collagen but not by adenosine diphosphate. Policosanol's antiplatelet mechanism of action differs from that of aspirin, and potentiates the antithrombotic effects of aspirin.

Bile Acid Absorption Inhibition

Modulation of HMG-CoA reductase and bile acid absorption inhibition have been proposed as mechanisms underlying the cholesterol-lowering activity of policosanol preparations. However, neither mechanism has been conclusively demonstrated for dotriacontanol as an isolated molecule.

Plant Growth Regulation (Non-Human Context)

It is important to note that dotriacontanol's best-characterized biological activity outside the polycosanol literature is as a plant growth regulator. Dotriacontanol is a natural plant growth regulator, derived primarily from epicuticular waxes found on the surfaces of leaves and other plant parts. This activity is specific to plant physiology and is not relevant to human supplementation.

6. Scientific Evidence by Area of Use

A critical framing note: There are no published human clinical trials examining dotriacontanol as an isolated compound. All clinical data pertain to policosanol mixtures in which dotriacontanol is a minor-to-moderate component. Any health effects attributed to the mixture cannot be ascribed solely to dotriacontanol.

6.1 Cardiovascular and Lipid-Lowering Effects

Cuban Clinical Trials (Positive Evidence)

Early clinical studies showed that oral administration of sugar cane policosanol within a range of 5–20 mg/day reduces plasma total cholesterol (TC) and LDL-C levels and increases HDL-C in healthy and hypercholesterolaemic individuals. A 6-month double-blind study in type II hypercholesterolaemia reported that based on mean values of LDL-cholesterol at study completion, the mean percent reductions from baseline were 27.4% and 28.1% for the 20 and 40 mg/day groups respectively, and both doses were similarly effective in changing all the other lipid profile parameters.

A meta-analysis of Cuban placebo-controlled trials found: Policosanol was associated with a lowering of total cholesterol (WMD: −0.58 mmol/L, 95% CI −0.87 to −0.30 mmol/L), a lowering of LDL-c (WMD: −0.71 mmol/L, 95% CI −1.02 to −0.40 mmol/L), and an elevation of HDL-c (WMD: 0.13 mmol/L, 95% CI 0.09 to 0.16 mmol/L) when all placebo-controlled trials were included (17 studies, n=1,204).

Independent (Non-Cuban) Trials (Negative Evidence)

Beginning around 2005, independent research groups substantially challenged the Cuban findings. One rigorous trial conducted in Germany used the same formulation of policosanol (from Dalmer labs) as the Cuban trials, over a range of doses (10–80 mg), and also observed no consistent or significant impacts to lipid profiles relative to placebo. A Canadian randomized, double-blind crossover study in 21 hypercholesterolaemic volunteers found: no significant difference between treatment and control groups in plasma total, LDL-, HDL-cholesterol, and triacylglycerol concentrations, concluding that present results show no beneficial effects of Cuban SCPs on lipid indicators in hypercholesterolemic persons and question the clinical usefulness of policosanol mixtures as cholesterol-lowering nutraceutical agents.

Another randomized controlled trial (n=40) found: No significant differences in the change in LDL cholesterol were observed between the placebo and policosanol groups. Also, no significant changes in secondary outcome measures, including total cholesterol, HDL cholesterol, triacylglycerol, C-reactive protein, and NMR-determined profiles were observed. Policosanol was well tolerated, and no significant adverse events were noted. Policosanol does not alter the serum lipid profile over an 8-week period in adults with mild hypercholesterolemia.

When meta-analyses disaggregated Cuban from non-Cuban trials, the picture became clear: The lipid-modulating effects were driven by the Cuban trials, such that in the trials conducted outside of Cuba (7 studies, n=360), policosanol did not have a significant effect on total cholesterol, LDL-c, or HDL-c. The current state of evidence is therefore inconsistent and inconclusive, with the large body of positive data originating predominantly from a single Cuban research group whose results have not been independently replicated.

Recent Korean Studies (Mixed Positive Evidence)

More recent studies using standardized Cuban policosanol (Raydel®) in East Asian populations have produced some positive signals. A small open-label study (n=25 subjects across three groups) found that subjects who consumed policosanol daily (10 mg/day) for 8 weeks showed systolic blood pressure significantly lowered to 4% (7 mmHg, p=0.022) from initial levels in certain groups. Serum triglyceride levels decreased to 28 and 26% from initial levels in two groups, and the percentage of HDL-cholesterol in total cholesterol was elevated in all subjects. These results are preliminary, from small samples, and should be interpreted with caution.

6.2 Antiplatelet and Antithrombotic Effects

A 2-week randomized, double-blind, placebo-controlled trial investigated the effects of policosanol on platelet aggregation and thromboxane B2 and prostacyclin production after stimulation with collagen in healthy volunteers. Volunteers received policosanol (10 mg/day) for 15 days, and platelet aggregation was determined at baseline and after 15 days of treatment. Significant reductions of arachidonic acid- and collagen-induced platelet aggregation were observed.

A dose-escalation RCT (n=37) found: antiplatelet effects of policosanol were successfully enhanced throughout the study, suggesting a dose-dependent relationship. No significant effect was reached during the first dosing period (10 mg/day), but significant reductions of epinephrine- and ADP-induced platelet aggregation were observed at 20 mg/day. A significant inhibition of platelet aggregation induced by all agonists was observed at the last dosing step (40 mg/day). Coagulation time remained unchanged during the trial.

Evidence strength for antiplatelet effects: Moderate, based on several small RCTs. These studies examined the policosanol mixture, not dotriacontanol specifically. Clinical significance of antiplatelet effects has not been established relative to hard cardiovascular outcomes.

6.3 Anti-Inflammatory Activity (Preclinical / Plant-Extract Level)

No clinical trials have investigated the anti-inflammatory effects of dotriacontanol in humans. At the plant-extract level, Bougainvillea × buttiana is an ornamental plant with antioxidant, anti-inflammatory, and cytotoxic activities, which has been traditionally used to treat respiratory diseases. A study of the acetonic extract of B. × buttiana var. Rose — which contained 1-dotriacontanol as a major component — found that the extract decreased nociceptive behaviors in murine pain models and significantly inhibited edema formation. These are whole-extract results; the contribution of dotriacontanol specifically cannot be attributed from this data.

In the context of RYR, the broader plant from which dotriacontanol has been isolated, RYR has been the subject of several pharmacological investigations due to its various ethnomedicinal uses. Studies have demonstrated that RYR exhibits a wide range of biological properties with hypolipidemic, anti-atherosclerotic, anti-cancer, neurocytoprotective, hepatoprotective, anti-osteoporotic, anti-fatigue, anti-diabetic, anti-obesity, immunomodulatory, anti-inflammatory, and anti-hypertensive activities. These activities belong to the complex RYR profile and cannot be attributed to dotriacontanol.

Evidence strength for anti-inflammatory effects: Preliminary and indirect. Evidence exists only for plant extracts containing dotriacontanol alongside numerous other compounds. No human data exists.

6.4 Wound Healing

The dermal wound healing property of fresh leaves of Tridax procumbens — from which dotriacontanol has been isolated — is well documented in regional literature. In an excision wound model, juice of fresh leaves of T. procumbens was administered to rabbits. An equivocal response was elicited wherein enhanced re-epithelization of wound was recorded on one hand, and retardation of scar contraction and granulation on the other. It was postulated that extract of T. procumbens is essentially pro-healing but also has corticotropic influence. These studies evaluated whole-plant extracts, not isolated dotriacontanol, and there are no human clinical data for this application.

6.5 Cardiovascular Outcomes Beyond Lipids

In addition to improving serum lipids, some studies evaluated policosanol in reduction of LDL oxidation, platelet aggregation, smooth muscle proliferation and blood pressure. Moreover, policosanol has favorable effects on intermittent claudication, possibly due to its effects on platelet aggregation and endothelial function. Clinical trials indicate that policosanol may have applications in the treatment of familial (type II) and diabetes-related hypercholesterolemia, as well as intermittent claudication. These findings are from the Cuban literature and have been subject to the same replication concerns described above.

7. Body Systems and Health Areas

• Cardiovascular system: Implicated via policosanol membership in lipid modulation (total cholesterol, LDL-C, HDL-C), antiplatelet activity, and possible effects on endothelial function. Evidence is mixed and largely applies to the mixture.
• Hematological system: Platelet aggregation inhibition via thromboxane A2 modulation, documented in RCTs of policosanol mixtures.
• Integumentary system: Associated (via source plants such as T. procumbens) with wound healing in traditional and preclinical contexts only.
• Hepatic system: HMG-CoA reductase modulation and LDL receptor upregulation implicate hepatic cholesterol metabolism.
• Inflammatory pathways: Preclinical data from source plant extracts suggest possible anti-inflammatory activity; no human data exists for dotriacontanol specifically.

8. Dosage Forms and Reported Dosages

Because dotriacontanol is not typically marketed or studied as an isolated compound for human use, dosage information derives from policosanol mixture studies. The percentage of dotriacontanol in any given dose depends entirely on the source and preparation.

• Policosanol is typically initiated at 5 mg/day and titrated up to 20 mg/day for hypercholesterolemia.
• Adjunctive use of 40 mg/day for 30 days has been used with antiplatelet regimens after percutaneous stent implantation.
• A dose-escalation RCT in 37 healthy volunteers used policosanol 10 mg/day for 7 days, doubled to 20 mg/day for the next 7 days, then doubled again to 40 mg/day.
• In a study examining HDL functionality, subjects consumed policosanol (10 mg/day) for 8 weeks.
• Another randomized crossover study used 10 mg of SCP per day incorporated in margarine for 28 days.

Given that dotriacontanol constitutes approximately 4–10% of sugar cane policosanol and 13–21% of beeswax policosanol, a daily dose of 10 mg of sugar cane policosanol would deliver roughly 0.4–1.0 mg of dotriacontanol per day, and a 20 mg dose would deliver approximately 0.8–2.0 mg. These are rough approximations based on published compositional data and are not equivalent to studied doses of isolated dotriacontanol.

9. Safety Considerations and Drug Interactions

General Tolerability

At dosages of up to 20 mg per day, policosanol is safe and well tolerated, as studies of more than 3 years of therapy indicate. In a randomized controlled trial, policosanol was well tolerated, and no significant adverse events were noted. Advantages of policosanol are its good tolerability and extremely low incidence of adverse events (side effects), which does not require frequent laboratory tests.

Platelet-Related Bleeding Risk

Several studies have shown that policosanol supplementation reduces platelet aggregation. Although this could provide protection against thrombotic events, it could also be associated with bleeding tendencies. To date, no published clinical trials have reported the occurrence of bleeding or hemorrhagic events during policosanol supplementation.

Drug Interactions — Anticoagulants and Antiplatelets

Because of policosanol's potential effects on platelet aggregation, caution is warranted if it is used concurrently with anticoagulants (e.g., warfarin) or antiplatelet agents (e.g., aspirin, clopidogrel, prasugrel). However, a study in 11 healthy men receiving warfarin 25 mg before and after treatment with policosanol 10 mg twice daily for 2 weeks found no effect of policosanol on the pharmacokinetics of (S)- or (R)-warfarin. Policosanol also did not alter the response to warfarin on platelet aggregation.

Because of its effects on platelet adhesiveness, policosanol can have additive effects with all anticoagulant and antiplatelet medications.

Pregnancy and Lactation

Information regarding safety and efficacy in pregnancy and lactation is lacking. There has been one published report on the perinatal and postnatal effects of policosanol in an animal model. In that study, pregnant Sprague-Dawley rats were administered policosanol at doses of up to 500 mg/kg/day from day 15 of pregnancy to day 21 post-parturition. Human data for this population does not exist.

Limitations of Existing Safety Data

Safety data reviewed herein apply to policosanol mixtures and cannot be exclusively attributed to dotriacontanol. No toxicological, pharmacokinetic, or safety studies have been published specifically for isolated dotriacontanol in human subjects. The oral absorption and bioavailability of policosanol are limited and their exact lipid-lowering mechanisms have not been adequately elucidated.

10. Summary of Evidence Strength

The following characterization applies to the policosanol mixture context, as no isolated-dotriacontanol clinical data exist:

• Lipid-lowering effects: Evidence is mixed and contested. A large body of Cuban RCTs reported significant effects; independent international trials have largely failed to replicate these results. Meta-analytic data indicate that effects may be confined to Cuban-sourced studies with methodological questions.
• Antiplatelet activity: Evidence is preliminary but moderately consistent from small, short-duration RCTs in healthy volunteers and patients. Dose-dependent effects on arachidonic acid– and collagen-induced aggregation have been demonstrated. Clinical significance is uncertain.
• Anti-inflammatory and wound healing properties: Evidence is preclinical only, derived from in vitro and animal studies of whole plant extracts containing dotriacontanol alongside other compounds. No human trials exist.
• Safety profile: Policosanol mixtures appear well tolerated at doses up to 20–40 mg/day in short-to-medium-term studies. Bleeding risk is theoretical rather than documented, though theoretical drug interactions with anticoagulants and antiplatelets are relevant.

References

• PubChem CID 96117 — Dotriacontanol. National Institutes of Health (NIH) / National Center for Biotechnology Information.
• ChemicalBook. 1-Dotriacontanol (CAS 6624-79-9). ChemicalBook, 2022.
• Wikipedia. 1-Dotriacontanol. Wikimedia Foundation.
• Zhu Y, et al. Red Yeast Rice: A Systematic Review of the Traditional Uses, Chemistry, Pharmacology, and Quality Control of an Important Chinese Folk Medicine. Frontiers in Pharmacology, 2019. PMC6901015.
• Zhu Y, et al. Red Yeast Rice: A Systematic Review. Frontiers in Pharmacology, 10:1449, 2019.
• Kim J, et al. Consumption of policosanol enhances HDL functionality via CETP inhibition and reduces blood pressure and visceral fat. Lipids in Health and Disease, 2017. PMC5360427.
• Korean policosanol study. Cuban Sugar Cane Wax Alcohol Exhibited Enhanced Antioxidant, Anti-Glycation and Anti-Inflammatory Activity in Reconstituted HDL. PMC9965296.
• Dulin MF, et al. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. American Journal of Clinical Nutrition, 2006.
• Kassis AN, Jones PJH. Lack of cholesterol-lowering efficacy of Cuban sugar cane policosanols in hypercholesterolemic persons. American Journal of Clinical Nutrition, 84(5):1003–1008, 2006.
• Arruzazabala ML, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacological Research, 34(5-6):181–185, 1996.
• Arruzazabala ML, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. PubMed PMID 9076841.
• Valdes S, et al. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins, Leukotrienes and Essential Fatty Acids, 58(1):61–64, 1998.
• Austin Publishing Group. Policosanol and Human Health. Austin Journal of Agriculture and Crop Sciences.
• ScienceDirect Topics. Policosanol — overview. Agricultural and Biological Sciences.
• Drugs.com Natural Products Database. Policosanol: Uses, Benefits & Dosage.
• Medscape. Policosanol. Pharmacological and clinical overview.
• Alzheimer's Drug Discovery Foundation. Cognitive Vitality Report: Policosanol.
• Wongwaiwech D, et al. Comparison of the policosanol contents in commercial health foods and policosanol stability in enriched rice bran oil. Food Production, Processing and Nutrition, 2024.
• ResearchGate. Chemical constituents of Agrimoniae Herba, including dotriacontanol.
• Varma MM, Gupta MM. Lipid constituents of Tridax procumbens. Phytochemistry, 1988.
• ScienceDirect. Phytochemistry and pharmacological aspects of Tridax procumbens (L.): A systematic and comprehensive review. Phytomedicine Plus, 2021.
• Jain S, et al. Evaluation of Wound Healing Potential of Topical Formulation of Leaf Juice of Tridax procumbens L. in Mice. PMC3309652.
• Antinociceptive and Anti-Inflammatory Activities of Acetonic Extract from Bougainvillea x buttiana (var. Rose). PMC11357402, 2024.
• Arabian Journal of Chemistry. Structural analysis of tiliroside and quercetrin from Malvastrum coromandelianum — dotriacontanol identified as phytoconstituent.
• US Patent 6,822,004. Polycosanols from Ericerus pela wax. US Patent Office.
• Rahimi R, et al. The effects of policosanol supplementation on creatinine: a systematic review and dose–response meta-analysis of RCTs. BMC Complementary Medicine and Therapies, 2025.